Pharma donations to patient groups in Canada are shrouded in mystery
Donation data reported on websites by drug makers and patient advocacy groups in Canada that receive industry funding is “haphazard, inconsistent and incomplete.”
D onation data reported on websites by drug makers and patient advocacy groups in Canada that receive industry funding is “haphazard, inconsistent and incomplete,” underscoring the difficulties in deciphering the influence these companies may have on patient interests, a new analysis finds. Specifically, information about the value of donations made by drug companies, the years in which contributions were given, and the percent of income the money represented for patient groups was limited. Consequently, donations made and received often could not be matched, according to the analysis in the I
related reading
- Canada’s laws on pharmaceutical intellectual property: the case for fundamental reformncbi.nlm.nih.gov
- Inside the Mafia of Pharma Pricing - BIG by Matt Stollerthebignewsletter.com
- The pharma industry from Paul Janssen to today: why drugs got harder to develop and what we can do about it | Alex’s blogatelfo.github.io
- Where are all the trillion dollar biotechs?ladanuzhna.xyz
- How PBMs can use private-labelled drug products as a great escape from anti-steering policies - 46brooklyn Research46brooklyn.com
- Black Canadians face barriers when donating blood despite critical need, study saystheglobeandmail.com
- Curious cases of financial engineering in biotechowlposting.com
- Canada Hands Out Billions to Corporations. What Are We Getting Back? | The Walrusthewalrus.ca
- What a time to be an oncologist - by Olivia Webb Kosloffacutecondition.com
- The latest orphan drug exemptions may not be warranted, analysis findsstatnews.com
- Pharma Virumque | Slate Star Codexslatestarcodex.com
- Competition Bureau investigating high tech price-fixing by Canadian landlordsbreachmedia.ca